恩度治疗非小细胞肺癌30例临床疗效及安全性观察  

Clinical Efficacy and Safety of Endostar in Treating 30 Cases of Non- Small Cell Lung Cancer

作　　者：蔡萍[1] 姜亚莉[1] 顾平荣[2] 刘申香[1] 黄富宏[1] 

机构地区：[1]江苏省扬州市第一人民医院,江苏扬州225001 [2]江苏省苏北人民医院,江苏扬州225000

出　　处：《中国药业》2015年第8期58-60,共3页China Pharmaceuticals

基　　金：江苏省药学会-百特生物药学基金项目;项目编号:苏药学会字[2013]69号

摘　　要：目的观察恩度联合化学治疗(简称化疗)治疗非小细胞肺癌的临床疗效及安全性。方法将60例非小细胞肺癌患者随机分为两组,各30例。治疗组患者采用恩度联合化疗,对照组患者单用化疗。结果治疗组患者的总有效率为83.33%,明显高于对照组的70.00%(P<0.05),但血清血管内皮生长因子(VEGF)水平无显著变化;两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论恩度联合化疗治疗非小细胞肺癌,能提高治疗总有效率且安全性良好,但VEGF变化不明显。Objective To observe the clinical effect of the Endostar combined with chemotherapy in treating non- small cell lung cancer （NSCLC）.nethods Totally 60 patients with NSCLC were randomly divided into two groups,30 cases in each group. The treatment group adopted the chemotherapy combined with Endostar,while the control group treated with chemotherapy alone. Results The total ef- fective rate in the treatment group was 83.33% ,which was significantly higher than 70. 00% in the control group（P 〈 0. 05）. But there was no significant change in serum VEGF level. The adverse reactions had no statistically significant differences between the two groups（ P 〉 0. 05）. Conclusion Endostar combined with chemotherapy in treating NSCLC can improve the total effective rate, but the VEGF change is not obvious.

关 键 词：恩度 非小细胞肺癌 临床疗效 血管内皮生长因子 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]